Rare Hemophilia Factors Market (2025 - 2030)

Rare Hemophilia Factors Market Trends

The global rare hemophilia factors market size was estimated at USD 338.3 million in 2024 and is projected to grow at a CAGR of 6.4% from 2025 to 2030. The increasing awareness of bleeding disorders and the rising incidence of hemophilia worldwide drives market growth worldwide. In 2023, approximately 219,000 cases were confirmed, with around 836,000 patients estimated globally, of which about 284,000 had severe forms, underscoring the need for effective treatments, including prophylactics for those requiring specialized care.

Increasing regulatory approvals for innovative factor concentrates have further stimulated market growth. For instance, in August 2022, the U.S. FDA approved Rebinyn, a recombinant coagulation factor IX concentrate targeted at routine prophylaxis and treatment during bleeding episodes. Such approvals enhance treatment options, benefitting patients and driving demand for specific clotting factors tailored for rare hemophilia types. Moreover, the COVID-19 pandemic impacted ongoing clinical trials, causing postponements that could delay new therapies. However, this setback has not deterred key players such as Novo Nordisk and CSL Behring from increasing research and development (R&D) activities, leading to a spike in novel treatments entering the market.

Government initiatives have played a crucial role by facilitating the diagnosis and treatment of these conditions. Policies such as the U.S. Orphan Drug Act have resulted in the approval of numerous orphan drugs, including therapies for rare hemophilia. These initiatives bolster patient and practitioner awareness about hemophilia disorders, promoting earlier diagnosis and accelerating treatment uptake. Furthermore, organizations such as the International Rare Diseases Research Consortium (IRDiRC) aim to develop new therapies and provide funding for R&D, fueling market expansion.

The rising adoption of prophylactic treatments among patients with severe hemophilia is aiding market growth further. Long-term prophylactic regimens, such as those recommended with NovoThirteen (rFXIII-A), significantly reduce joint damage and improve quality of life. With government mandates and increased awareness driving this trend, the market is well-positioned for continued growth, addressing critical unmet needs in the management of rare hemophilia disorders and ultimately improving patient outcomes. For instance, in January 2024, Takeda Pharmaceutical and Protagonist Therapeutics announced a worldwide license agreement for rusfertide, with Takeda assuming global commercialization rights and USD 300 million upfront payment in the U.S. market.

Factor Deficiency Type Insights

Factor VII deficiency dominated the market and accounted for a share of 35.1% in 2024. Factor VII deficiency is the most prevalent rare congenital bleeding disorder, with an estimated occurrence of 1 in 300,000 to 500,000 individuals, according to the National Hemophilia Foundation. The demand for treatment options, such as NovoSeven, a recombinant factor VIIa, is influenced by its availability. Initiatives by organizations such as the World Federation of Hemophilia aim to enhance diagnosis and treatment, increasing awareness of rare hemophilia disorders.

Factor XIII deficiency is expected to grow at the fastest CAGR of 7.1% over the forecast period. Factor XIII deficiency is a rare genetic bleeding disorder with an estimated prevalence of 1 in 2,000,000 to 5,000,000 people. Recent advancements in treatment have led to the development of recombinant FXIII Concentrate, approved in Canada and the US. Prophylactic therapy and replacement therapy are recommended to prevent or minimize symptoms.

Drug Class Insights

Recombinant therapies led the market and accounted for a share of 50.3% in 2024. Advancements in hemophilia treatment are propelled by significant research and development in biotechnology, leading to innovative therapies such as extended half-life treatments. Increased R&D activity among key market players has resulted in the introduction of novel factor concentrates. Enhanced availability of recombinant therapies and emerging gene therapies improves patient outcomes, supported by stringent regulatory policies that elevate awareness and ensure rigorous drug approval processes.

Prophylactic treatments are expected to register the fastest CAGR of 7.5% over the forecast period, driven by superior patient outcomes, including fewer joint bleeds and improved quality of life. In 2023, prophylaxis emerged as a preferred choice for severe cases. Increased adoption of regular clotting factor infusions and advancements in gene therapies further enhance treatment effectiveness and minimize bleeding risks, contributing to overall market growth.

Distribution Channel Insights

Hospital pharmacies held the largest market share of 59.9% in 2024. Hospital pharmacies serve as a vital distribution channel for hemophilia drugs, alongside retail and online pharmacies. Currently, the distribution mix is approximately 60% specialty pharmacy/home, 30% Hemophilia Treatment Centers (HTCs), and 10% hospitals. While most patients self-infuse at home, they may seek emergency care, underscoring the importance of hospital pharmacies in acute situations and during hospitalizations.

Online pharmacies are projected to grow at the fastest CAGR of 9.2% over the forecast period, fueled by the rising adoption of digital health platforms and telemedicine services. Patients benefit from the convenience of ordering medications from home, minimizing in-person visits. Companies such as Walgreens are enhancing this experience with streamlined services, including home delivery, automatic refills, and telehealth consultations, further propelling market growth.

Regional Insights

North America rare hemophilia factors market dominated the global market with a revenue share of 38.7% in 2024. Advancements in FDA-approved therapies, heightened awareness of bleeding disorders, and a significant patient prevalence are driving market growth in the region. Approximately 14,816 cases of the disease were recorded in the U.S. in 2020, with Canada recording 4,709 in the same year. Moreover, government initiatives aimed at diagnosis and cost reduction and the presence of key players such as Novo Nordisk and Pfizer further drive market growth.

U.S. Rare Hemophilia Factors Market Trends

The rare hemophilia factors market in the U.S. dominated the North America rare hemophilia factors market with a revenue share of 90.1% in 2024. Government initiatives aimed at enhancing diagnosis rates and lowering treatment costs significantly contribute to growth, supported by organizations such as the National Organization for Rare Disorders (NORD) offering research grants. Therapeutic advancements have led to the approval of new FDA agents, while increased awareness of bleeding disorders, particularly through campaigns by the National Hemophilia Foundation, fosters adoption. For instance, in April 2024, Octapharma USA announced that the FDA granted orphan drug exclusivity for wilate as the first VWF concentrate for prophylaxis in all types of von Willebrand disease in the U.S.

Europe Rare Hemophilia Factors Market Trends

Europe rare hemophilia factors market held substantial market share in 2024, fueled by heightened research and development activities that stimulate growth. Favorable government initiatives support market advancements, while growing public awareness of hemophilia contributes positively to the landscape. These elements collectively foster an environment conducive to the expansion of the rare hemophilia factors market in Europe. For instance, in July 2024, CSL Behring announced the treatment of two hemophilia B patients with HEMGENIX gene therapy at Hemophilia Treatment Centers in France, marking its first real-world administration in Europe.

The rare hemophilia factors market in Germany is expected to grow in the forecast period. Increasing awareness of rare hemophilia factors and their treatment options plays a crucial role in driving growth. The recent celebration of 15 years of the German Haemophilia Registry underscores the importance of data collection for blood clotting disorders. Moreover, technological advancements in diagnostics and treatment, a rising incidence of rare hemophilia factors, orphan drug approvals, and heightened demand for effective therapies are significant contributors. Furthermore, the growing adoption of prophylactic treatments, involving regular administration of clotting factor replacement therapy, also supports market expansion.

Asia Pacific Rare Hemophilia Factors Market Trends

Asia Pacific rare hemophilia factors market is expected to register the fastest CAGR of 6.1% in the forecast period. Growing public awareness of bleeding disorders and the large patient populations in emerging economies such as China and India further enhance market potential. Moreover, collaborations among key players and the rising prevalence of hemophilia are expected to drive market growth throughout the forecast period.

India rare hemophilia factors market is expected to grow at the fastest rate of 9.7% over the forecast period. The rising prevalence of rare hemophilia factor disorders, driven by enhanced awareness and improved diagnostic tools, serves as a primary market driver. The expanding healthcare infrastructure in developing countries plays a significant role in this growth. Ongoing research and development initiatives aimed at improving treatment options, alongside collaborations between pharmaceutical companies, research institutions, and patient advocacy groups, further accelerate advancements in the field. For instance, in December 2024, the Department of Biotechnology (DBT) and Centre for Stem Cell Research (CSCR) at the Christian Medical College, Vellore, in India successfully conducted the first-in-human gene therapy for Haemophilia A, achieving zero annualised bleeding rates in five enrolled participants.

Key Rare Hemophilia Factors Company Insights

Some key companies operating in the market include Takeda Pharmaceutical Company Limited; Biogen; Novo Nordisk A/S; Bayer AG; among others. The market exhibits moderate competition, with key players prioritizing product portfolio expansion and regulatory approvals through strategic partnerships and enhanced research and development efforts.

• BioMarin Pharmaceutical Inc. specializes in rare genetic disease treatments, with ROCTAVIAN, a gene therapy approved in Europe for severe hemophilia A in adults without inhibitors or AAV5 antibodies, providing a treatment option for this population.

• Bayer AG is a leading player in the rare hemophilia factors market, developing therapies for hemophilia and holding a substantial market share, capitalizing on its expertise in addressing genetic bleeding disorders and uncontrolled bleeding issues.

Recent Developments

• In December 2024, Novo Nordisk announced the U.S. FDA approval of Alhemo injection as a once-daily prophylactic treatment to prevent bleeding episodes for adults and children 12+ in the U.S. with hemophilia A or B.

• In September 2024, Pfizer announced that the EMA’s CHMP adopted a positive opinion for marstacimab, potentially marking the first once-weekly subcutaneous treatment for severe hemophilia A and B in Europe.

• In August 2024, BioMarin announced a strategic focus shift for ROCTAVIAN towards the U.S., Germany, and Italy, aiming for profitability by the end of 2025 through reduced operating expenses.

Rare Hemophilia Factors Market